Zydus Cadila has received final approval from the USFDA to market Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg. (US RLD: Trilafon® Tablets)
This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group's formulation manufacturing facility at Baddi.
The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.273.4 as compared to the previous close of Rs. 263.85. The total number of shares traded during the day was 118778 in over 2488 trades.
The stock hit an intraday high of Rs. 279.3 and intraday low of 258.6. The net turnover during the day was Rs. 32339334.